公开(公告)号：US20230364021A1

公开(公告)日：2023-11-16

申请号：US18354293

申请日：2023-07-18

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/16 ,  A61K31/44 ,  A61K9/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/32

CPC classification number: A61K9/1688 ,  A61K31/44 ,  A61K9/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/32

Abstract: Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, as are methods for their use, and methods for making such particles.

公开(公告)号：US20230142591A1

公开(公告)日：2023-05-11

申请号：US18053491

申请日：2022-11-08

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Aranza Barreda ABARCA ,  Shelby CLARK ,  Joseph FARTHING ,  Mark WILLIAMS ,  Gere DIZEREGA ,  Michael BALTEZOR

IPC: A61K31/454 ,  A61K9/00 ,  A61K9/16

CPC classification number: A61K31/454 ,  A61K9/008 ,  A61K9/1688

Abstract: Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.

公开(公告)号：US20220241257A1

公开(公告)日：2022-08-04

申请号：US17381705

申请日：2021-07-21

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K31/44 ,  A61K9/16

Abstract: The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, methods for their use, and methods for making such particles.

公开(公告)号：US20210387961A1

公开(公告)日：2021-12-16

申请号：US17401654

申请日：2021-08-13

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61P31/04 ,  A61K9/14 ,  A61K9/00

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20230142186A1

公开(公告)日：2023-05-11

申请号：US18053557

申请日：2022-11-08

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Aranza Barreda ABARCA ,  Shelby CLARK ,  Joseph FARTHING ,  Mark WILLIAMS ,  Gere DIZEREGA ,  Michael BALTEZOR

IPC: A61K31/55 ,  A61K9/16

CPC classification number: A61K31/55 ,  A61K9/1688 ,  A61K9/16

Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.

公开(公告)号：US20200247780A1

公开(公告)日：2020-08-06

申请号：US16650670

申请日：2018-09-28

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61K9/14 ,  A61K9/00 ,  A61P31/04

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20220370355A1

公开(公告)日：2022-11-24

申请号：US17812479

申请日：2022-07-14

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/14 ,  A61K31/5365 ,  A61K47/26

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.

公开(公告)号：US20220023215A1

公开(公告)日：2022-01-27

申请号：US17381786

申请日：2021-07-21

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/14 ,  A61K31/5365 ,  A61K47/26

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm.